Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved crizotinib for reimbursement as a treatment option for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer, and whose ALK rearrangement has been demonstrated by an accurate and validate test method.
This is written in the approval document as:
Treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
Citation
Crizotinib Monotherapy, 2020, version number 6, NCCP National SACT Regimen, NCCP, viewed 19/12/2023, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/243-crizotinib-monotherapy-regimen.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | v::ALK | Non-Small Cell Lung Cancer | Crizotinib |